system
vascul
character
blood
vessel
inflamm
may
lead
tissu
injuri
vascular
stenosi
occlus
aneurysm
ruptur
apart
rel
common
vasculitid
purpura
hsp
kawasaki
diseas
kd
primari
vasculit
syndrom
rare
childhood
present
associ
signific
morbid
mortal
caus
major
childhood
vasculitid
unknown
although
like
complex
interact
environment
factor
infect
inherit
host
respons
trigger
diseas
determin
vascul
phenotyp
chapter
summar
find
recent
studi
relat
pathogenesi
system
vascul
consid
hsp
kd
antineutrophil
cytoplasm
antibodi
anca
associ
vascul
polyarter
nodosa
takayasu
arter
ta
rarer
form
vascul
beyond
scope
chapter
reader
refer
elsewher
addit
discuss
current
therapeut
approach
ongo
challeng
field
paediatr
vascul
research
mani
occurr
paediatr
patient
preced
upper
respiratori
tract
infect
sever
agent
implic
includ
group
streptococci
varicella
hepat
b
viru
parvoviru
mycoplasma
campylobact
yersinia
note
masuda
et
al
show
nephritisassoci
plasmin
receptor
naplr
group
streptococc
antigen
may
pathogenet
role
subset
patient
hsp
nephriti
among
children
biopsi
proven
hsp
nephriti
segment
global
mesangi
deposit
naplr
antigen
compar
children
nonhsp
nephriti
glomerular
diseas
half
children
iga
nephropathi
exact
pathophysiolog
mechan
relationship
naplr
hsp
nephriti
need
howev
investig
far
singl
infecti
agent
consist
identifi
like
genet
control
host
respons
determin
whether
individu
develop
hsp
respons
infecti
trigger
despit
fact
caus
hsp
unknown
like
iga
pivot
role
pathogenesi
diseas
hypothesi
support
almost
univers
deposit
iga
lesion
vascular
tissu
skin
renal
biopsi
demonstr
deposit
iga
mainli
wall
dermal
capillari
postcapillari
venul
mesangium
addit
serum
iga
level
report
increas
acut
phase
diseas
proport
patient
circul
igacontain
immun
complex
cryoglobulin
studi
found
iga
antineutrophil
cytoplasm
antibodi
igaanca
proport
patient
hsp
other
shown
increas
igarheumatoid
factor
igaanticardiolipin
antibodi
recent
galactos
defici
olink
glycan
hing
region
report
adult
iga
nephropathi
children
hsp
aberrantli
glycosyl
protein
form
immun
complex
deposit
mesangium
bind
mesangi
cell
stimul
cellular
prolifer
overexpress
extracellular
matrix
compon
result
typic
renal
lesion
associ
hsp
recent
hiasano
et
al
show
complement
activ
altern
lectin
pathway
patient
hsp
nephriti
demonstr
complement
activ
promot
situ
glomerulu
form
iga
immun
complex
activ
complement
lead
format
chemotact
factor
turn
recruit
polymorphonuclear
leucocyt
site
deposit
polymorphonuclear
leucocyt
thu
recruit
chemotact
factor
caus
inflamm
necrosi
vessel
wall
concomit
thrombosi
subsequ
result
extravas
erythrocyt
haemorrhag
affect
organ
manifest
histolog
leucocytoclast
vascul
term
leucocytoclasi
refer
breakdown
white
blood
cell
lesion
tissu
particularli
characterist
nuclear
debri
nuclear
dust
observ
specif
hsp
sever
genet
polymorph
link
hsp
variou
popul
cohort
often
consist
result
across
multipl
studi
summar
tabl
mani
polymorph
relat
cytokin
cell
adhes
molecul
involv
modul
inflammatori
respons
endotheli
cell
activ
connect
hsp
hla
allel
convinc
genet
associ
three
cohort
itali
northwest
spain
turkey
drb
posit
associ
drb
neg
associ
hsp
two
three
studi
associ
hsp
turkish
cohort
associ
nephriti
spanish
cohort
null
allel
either
complement
factor
gene
shown
associ
hsp
multipl
cohort
differ
ethnic
differ
find
regard
associ
allel
associ
heterozygos
homozygos
null
allel
close
linkag
gene
hla
result
debat
signific
find
polymorph
angiotensinconvert
enzym
ace
gene
associ
risk
hsp
two
cohort
sever
addit
studi
focus
associ
ace
allel
risk
nephriti
without
consist
find
high
carriag
rate
mutat
mefv
recent
report
turkish
children
hsp
whole
howev
studi
natur
hamper
rel
small
patient
number
thu
lack
power
definit
necessarili
applic
racial
group
skin
involv
typic
purpura
gener
symmetr
affect
lower
limb
buttock
major
case
upper
extrem
involv
less
frequent
abdomen
chest
face
gener
unaffect
angioedema
urticaria
also
occur
around
two
third
children
joint
manifest
present
three
quarter
children
develop
abdomin
symptom
rang
mild
colic
sever
pain
ileu
vomit
haematemesi
melena
sometim
observ
complic
includ
intestin
perfor
intussuscept
acut
pancreat
also
describ
although
rare
complic
organ
less
frequent
involv
includ
central
nervou
system
cerebr
vascul
gonad
orchiti
may
confus
torsion
testi
lung
pulmonari
haemorrhag
report
hsp
nephriti
indic
case
affect
complic
renal
involv
present
vari
degre
sever
includ
isol
microscop
haematuria
proteinuria
microscop
macroscop
haematuria
acut
nephrit
syndrom
haematuria
least
two
hypertens
rais
plasma
creatinin
oliguria
nephrot
syndrom
usual
microscop
haematuria
mix
pictur
larg
major
case
hsp
requir
symptomat
treatment
nonsteroid
antiinflammatori
drug
nsaid
may
use
treat
arthralgia
associ
hsp
controversi
concern
use
corticosteroid
treatment
hsp
exist
regard
whether
reduc
sever
durat
diseas
decreas
risk
glomerulonephr
prevent
relaps
diseas
chartapisak
et
al
recent
systemat
review
publish
random
control
trial
rct
prevent
treatment
renal
involv
hsp
metaanalys
four
rct
evalu
prednison
therapi
present
hsp
show
signific
differ
risk
develop
persist
renal
involv
month
prednison
compar
placebo
specif
treatment
largest
trial
enrol
children
januari
januari
primari
outcom
urinari
proteincreatinin
ratio
year
measur
children
largest
studi
date
show
signific
benefit
prednison
placebo
prevent
persist
renal
diseas
said
could
still
role
earli
use
corticosteroid
patient
sever
extraren
symptom
abdomin
pain
arthralgia
suggest
find
studi
perform
ronkainen
et
al
prednison
mgkgday
week
wean
subsequ
week
effect
reduc
intens
abdomin
pain
joint
pain
prednison
prevent
develop
renal
symptom
effect
treat
present
renal
symptom
resolv
prednison
patient
treatment
compar
placebo
patient
note
nikibakhsh
et
al
report
recent
success
treatment
mycophenol
mofetil
mmf
recurr
skin
articular
gastrointestin
symptom
children
fail
respond
system
steroid
therapi
patient
rapidli
progress
glomerulonephr
crescent
chang
biopsi
uncontrol
data
suggest
treatment
may
compris
aggress
therapi
corticosteroid
cyclophosphamid
possibl
plasma
exchang
caus
crescent
nephriti
therapi
cyclosporin
azathioprin
cyclophosphamid
report
effect
hsp
common
caus
rapidli
progress
glomerulonephr
childhood
aggress
therapeut
approach
plasma
exchang
employ
case
treatment
option
import
select
case
yet
support
rct
addit
robust
clinic
trial
guid
therapi
hsp
nephriti
rapidli
progress
patient
may
exhibit
less
crescent
renal
biopsi
suboptim
gfr
heavi
proteinuria
necessarili
nephrot
rang
mani
would
advoc
corticosteroid
other
advoc
addit
cyclophosphamid
corticosteroid
hsp
nephriti
biopsi
show
diffus
prolif
lesion
sclerosi
crescent
chang
ongo
heavi
proteinuria
patient
greater
month
durat
proteinuria
ace
inhibitor
may
indic
limit
secondari
glomerular
injuri
although
evid
support
therapi
lack
major
children
hsp
make
full
unev
recoveri
evid
ongo
signific
renal
diseas
renal
involv
seriou
longterm
complic
hsp
narchi
et
al
systemat
review
publish
literatur
regard
longterm
renal
impair
children
hsp
persist
renal
involv
hypertens
reduc
renal
function
nephrot
nephrit
syndrom
occur
children
overal
incid
vari
sever
kidney
diseas
present
occur
children
isol
haematuria
andor
proteinuria
acut
nephriti
andor
nephrot
syndrom
acut
phase
aetiolog
kd
remain
unknown
current
felt
ubiquit
infecti
agent
produc
abnorm
immunolog
respons
genet
suscept
subject
result
characterist
clinic
pictur
pronounc
season
cluster
kd
case
led
hunt
infecti
agent
caus
howev
far
singl
agent
identifi
fact
recent
highlight
neg
result
emerg
studi
examin
potenti
link
coronaviru
infect
kd
taiwan
one
debat
regard
caus
kd
centr
around
mechan
immun
activ
convent
antigen
versu
superantigen
sag
sag
group
protein
share
abil
stimul
larg
proport
cell
tcell
repertoir
compar
one
million
cell
convent
antigen
bind
portion
tcell
receptor
chain
associ
major
histocompat
complex
mhc
class
ii
molecul
requir
antigen
process
sag
identifi
varieti
microorgan
includ
mani
bacteria
virus
isol
children
kd
abe
et
al
first
describ
select
expans
cell
kd
indic
tcell
hallmark
sagmedi
process
sinc
mani
similar
studi
examin
cell
repertoir
kd
examin
preval
serolog
convers
colon
sagproduc
organ
sag
also
respons
induct
coronari
arteri
diseas
murin
model
kd
discuss
detail
vivo
experiment
data
kd
section
howev
rowley
et
al
recent
report
three
fatal
case
kd
observ
iga
plasma
cell
infiltr
vascular
wall
acut
phase
ill
examin
clonal
iga
respons
use
revers
transcriptas
rt
pcr
lesion
vascular
tissu
research
observ
iga
respons
oligoclon
suggest
convent
ag
process
rather
sagdriven
one
although
debat
continu
regard
mechan
initi
immun
activ
differ
mechan
like
involv
final
common
pathway
immun
activ
respons
clinic
syndrom
regardless
cell
get
activ
massiv
immun
respons
characterist
kd
translat
system
inflamm
manifest
clinic
fever
cardiac
featur
kd
experiment
mice
develop
coronari
arter
respons
intraperiton
inject
lactobacillu
casei
wall
extract
lcwe
result
vascul
similar
kd
children
young
mice
age
week
suscept
lcweinduc
diseas
compar
older
mice
peripher
immun
activ
within
hour
lcwe
inject
follow
local
infiltr
cardiac
tissu
day
inflammatori
infiltr
compris
mainli
cell
inflammatori
respons
peak
day
post
inject
accompani
elastin
breakdown
disrupt
intima
media
well
aneurysm
format
day
addit
sag
found
within
lcwe
contribut
significantli
develop
vascular
diseas
common
featur
murin
model
human
diseas
includ
infecti
trigger
lead
immun
activ
diseas
suscept
young
time
cours
similar
seen
clinic
kd
similar
patholog
coronari
arter
respons
intraven
immunoglobulin
ivig
treatment
propos
diseas
model
support
vivo
experiment
data
mous
model
begin
immun
activ
microb
superantigen
activ
sag
found
lcwe
preferenti
expand
tlymphocyt
express
posit
cell
superantigen
activ
directli
correl
abil
induc
coronari
arter
mice
ablat
confirm
play
import
regulatori
role
diseas
induct
diseas
model
mice
absenc
activ
blockad
knockout
develop
coronari
diseas
lcwe
stimul
note
cell
found
affect
vessel
express
sagreact
famili
unexpect
find
consid
usual
fate
sagactiv
cell
activ
delet
apoptosi
moolani
et
al
shown
costimul
rescu
sagstimul
cell
apoptosi
furthermor
coronari
endothelium
transform
profession
antigenpres
cell
apc
upregul
costimulatori
molecul
driven
partial
tissuespecif
express
tolllik
receptor
tlr
increas
express
conjunct
stimul
ligand
lcwe
lead
increas
express
costimulatori
molecul
facilit
rescu
sagactiv
cell
continu
local
product
proinflammatori
cytokin
lead
exacerb
inflamm
coronari
vessel
wall
involv
transcript
regul
matrix
metalloproteinas
mmp
upregul
inhibit
product
follow
enzymat
activ
lead
elastin
breakdown
aneurysm
format
note
recent
alvira
et
al
shown
coronari
arter
associ
kd
suppress
elastin
degrad
inhibit
plasminmedi
activ
thu
strategi
block
use
marfan
syndrom
unlik
benefici
kd
lead
worsen
elastin
degrad
murin
model
kd
summari
sustain
local
immun
respons
togeth
persist
product
leucocyt
recruit
lead
upregul
proteolyt
activ
elastin
degrad
vessel
wall
damag
characterist
coronari
arteri
lesion
seen
kd
although
clinic
syndrom
occurr
epidem
suggest
infecti
caus
kd
genet
contribut
risk
suggest
much
higher
preval
diseas
japan
korea
elsewher
increas
preval
within
famili
increas
rel
risk
sibl
compar
gener
popul
recent
number
polymorph
identifi
appear
link
diseas
suscept
kd
risk
coronari
arteri
aneurysm
caa
polymorph
summar
tabl
gener
candid
gene
studi
kd
difficult
interpret
sinc
find
replic
inde
conflict
result
report
gene
evalu
multipl
cohort
furthermor
genomewid
linkag
studi
use
microsatellit
marker
japanes
famili
identifi
number
potenti
loci
finer
scale
studi
region
led
identif
link
group
singlenucleotid
polymorph
snp
inositol
c
itpkc
gene
associ
kd
odd
ratio
itpkc
mutat
associ
kd
japanes
also
us
caucasian
patient
particularli
risk
develop
coronari
arteri
lesion
addit
data
support
function
signific
one
polymorph
identifi
snp
led
reduc
splice
itpkc
gene
product
therefor
could
result
lower
mrna
concentr
note
howev
chi
et
al
subsequ
show
statist
signific
associ
itpkc
gene
snp
kd
coronari
arteri
lesion
taiwanes
children
first
genomewid
associ
studi
gwa
kd
notabl
assess
popul
stratif
replic
gwa
find
independ
cohort
gwa
caucasian
patient
follow
snp
genotyp
signific
snp
famili
fine
map
known
gene
near
snp
success
replic
led
identif
eight
put
novel
suscept
gene
odd
ratio
approxim
princip
clinic
featur
fever
persist
day
peripher
extrem
chang
redden
palm
sole
indur
oedema
subsequ
desquam
polymorph
exanthema
bilater
conjunctiv
injectioncongest
lip
oral
caviti
chang
reddeningcrack
lip
strawberri
tongu
oral
pharyng
inject
cervic
lymphadenopathi
acut
nonpurul
diagnosi
establish
accord
diagnost
guidelin
japan
kawasaki
diseas
research
committe
five
six
criteria
present
caa
present
fewer
featur
may
necessari
diagnost
purpos
cardiovascular
featur
import
manifest
condit
widespread
vascul
affect
predominantli
mediums
muscular
arteri
especi
coronari
arteri
coronari
arteri
involv
occur
untreat
case
addit
cardiac
featur
signific
proport
includ
pericardi
effus
electrocardiograph
abnorm
pericard
myocard
valvular
incompet
cardiac
failur
myocardi
infarct
anoth
clinic
sign
mayb
rel
specif
kd
develop
erythema
indur
site
bacil
bcg
inocul
system
involv
occur
includ
gastrointestin
tract
hepatobiliari
tract
hydrop
gall
bladder
well
recognis
central
nervou
system
seizur
mening
featur
auditori
system
deaf
skelet
system
arthropathi
urinari
system
earli
recognit
treatment
kd
aspirin
ivig
shown
unequivoc
metaanalysi
reduc
occurr
caa
preval
caa
invers
relat
total
dose
ivig
gkg
ivig
optim
dose
usual
given
singl
infus
metaanalysi
rct
compar
divid
lower
dose
ivig
mgkgday
consecut
day
versu
singl
infus
highdos
ivig
gkg
h
clearli
shown
even
though
regimen
benefit
singl
dose
gkg
greater
therapeut
effect
prevent
caa
howev
ivig
resist
occur
case
case
advoc
second
dose
ivig
andor
use
corticosteroid
regard
corticosteroid
use
ivig
resist
kd
appar
conflict
data
clinic
trial
inou
et
al
report
random
control
trial
kd
patient
assign
receiv
ivig
gkgday
two
consecut
day
given
h
ivig
plu
prednisolon
sodium
succin
mgkgday
three
time
daili
given
intraven
iv
inject
fever
resolv
oral
creactiv
crp
level
normal
patient
group
receiv
aspirin
mgkg
dipyridamol
mgkgday
addit
corticosteroid
associ
reduc
caa
compar
ivig
alon
receiv
ivig
antiplatelet
therapi
caa
month
compar
receiv
ivig
plu
corticosteroid
also
durat
fever
shorter
crp
decreas
rapidli
group
patient
receiv
corticosteroid
contrast
newburg
et
al
subsequ
multicent
random
doubleblind
placebocontrol
trial
examin
effect
addit
singl
dose
intraven
methylprednisolon
standard
therapi
found
corticosteroid
regimen
improv
caa
outcom
children
contrast
result
suggest
dose
durat
corticosteroid
may
critic
consid
adjunct
therapi
kd
infliximab
chimer
monoclon
antibodi
report
effect
treatment
ivigresist
kd
patient
fail
respons
singl
dose
ivig
receiv
infliximab
cessat
fever
follow
reduct
crp
recent
burn
et
al
report
multicentr
prospect
trial
second
ivig
infus
gkg
versu
infliximab
mgkg
children
acut
kd
fever
initi
fail
treatment
ivig
cessat
fever
within
h
subject
treat
infliximab
subject
retreat
ivig
signific
differ
observ
treatment
group
chang
baselin
laboratori
variabl
fever
echocardiograph
assess
coronari
arteri
report
encourag
rct
establish
optim
manag
kd
particular
ivigresist
kd
need
respect
multicentr
doubleblind
random
placebocontrol
trial
intend
assess
efficaci
etanercept
fusion
protein
combin
tnf
receptor
fc
compon
human
reduc
ivig
refractori
rate
treatment
acut
kd
ongo
convalesc
phase
condit
aneurysm
persist
antiplatelet
therapi
form
lowdos
aspirin
continu
long
term
aneurysm
resolv
presenc
giant
aneurysm
greater
mm
warfarin
recommend
addit
aspirin
patient
may
requir
coronari
angioplasti
revascular
procedur
ischem
symptom
aris
evid
obstruct
occur
acut
mortal
kd
japan
patient
develop
caa
acut
diseas
develop
coronari
arteri
stenos
risk
greater
larg
giant
aneurysm
howev
emerg
data
suggest
spite
seem
recoveri
longterm
cardiovascular
sequela
patient
kd
persist
adult
life
may
import
implic
pathogenesi
aav
still
fulli
elucid
clinic
well
experiment
data
strongli
suggest
role
autoimmun
respons
mpo
diseas
develop
accept
model
pathogenesi
suggest
anca
activ
cytokineprim
neutrophil
within
microvasculatur
lead
bystand
damag
endotheli
cell
rapid
escal
inflamm
recruit
mononuclear
cell
falk
et
al
demonstr
anca
vitro
activ
neutrophil
produc
reactiv
oxygen
speci
releas
lytic
enzym
process
requir
prime
neutrophil
prime
involv
stimul
neutrophil
low
dose
proinflammatori
cytokin
result
among
thing
surfac
express
neutrophil
membran
without
full
neutrophil
activ
interact
anca
prime
neutrophil
activ
anca
involv
interact
target
antigen
neutrophil
membran
also
particular
addit
reumaux
et
al
show
ancainduc
neutrophil
activ
occur
neutrophil
attach
surfac
float
circul
furthermor
radford
et
al
demonstr
anca
directli
activ
neutrophil
becom
firmli
adher
vessel
wall
may
obstruct
flow
initi
tissu
damag
contribut
pathogenesi
vascul
effect
block
antibodi
antibodi
detail
savag
et
al
show
activ
neutrophil
anca
caus
integrin
cytokin
receptormedi
adher
cultur
endotheli
cell
transmigr
across
endotheli
layer
addit
activ
neutrophil
anca
caus
conform
chang
integrin
enhanc
ligand
bind
role
adhes
molecul
interact
ancaactiv
neutrophil
vessel
also
support
immunohistolog
evid
upregul
adhes
molecul
glomerular
lesion
renal
biopsi
specimen
patient
aav
addit
bind
surfac
endotheli
cell
mpo
intern
endotheli
cell
differ
patholog
effect
exampl
intern
caus
endotheli
cell
apoptosi
wherea
mpo
caus
gener
intracellular
oxid
differ
mpo
interact
endotheli
cell
could
influenc
pattern
tissu
injuri
induc
antigen
react
anca
endotheli
cell
surfac
furthermor
new
evid
neutrophil
activ
anca
neutrophil
driven
acceler
apoptot
death
pathway
reactiv
oxygen
speci
neutrophil
develop
morpholog
featur
apoptosi
dysregul
coordin
cell
surfac
chang
normal
accompani
apoptosi
includ
delay
phosphatidylserin
express
could
contribut
failur
apoptot
cell
recogn
safe
remov
phagocyt
apoptot
neutrophil
eventu
disintegr
releas
cytotox
content
within
vascular
tissu
process
may
explain
leucocytoclasia
often
seen
vasculit
lesion
also
pertain
safe
clearanc
apoptot
neutrophil
two
studi
show
apoptot
neutrophil
express
myeloperoxidas
cell
surfac
act
opsonin
anca
apoptot
anca
opson
apoptot
neutrophil
phagocytos
macrophag
wherea
former
induc
antiinflammatori
respons
macrophag
releas
latter
taken
avidli
proinflammatori
induc
macrophag
releas
tnf
signal
cascad
lead
function
respons
superoxid
releas
begin
elucid
tyrosin
kinas
protein
kinas
c
known
involv
mitogenactiv
protein
kinas
requir
tyrosin
phosphoryl
activ
also
implic
particularli
tnfmediat
prime
furthermor
wg
granulomat
inflamm
display
sever
differ
morpholog
within
surround
inflammatori
background
poorli
form
epithelioid
cell
granuloma
scatter
histiocyt
giant
cell
langhan
type
palisad
histiocyt
around
central
necrosi
may
seen
mix
inflammatori
infiltr
wg
compos
lymphocyt
plasma
cell
neutrophil
eosinophil
monocyt
macrophag
histiocyt
giant
cell
sinc
cell
play
pivot
role
granuloma
format
alter
tcell
cytokin
respons
could
contribut
anomal
autoantigen
present
ectop
lymphoidlik
structur
sustain
autoimmun
skew
tcell
phenotyp
expans
cell
lack
express
seen
wg
expans
neg
cell
alreadi
evid
local
wg
increas
gener
diseas
abund
type
cc
chemokin
receptor
express
seen
granulomat
lesion
respiratori
tract
local
wg
appear
less
strong
gener
wg
moreov
fraction
type
produc
cell
present
circul
tissu
lesion
gener
local
wg
data
suggest
aberr
type
respons
favour
granuloma
format
might
play
role
initi
wg
ectop
present
wegen
autoantigen
autoimmun
might
sustain
within
inflammatori
lesion
skew
tcell
cytokin
respons
progress
local
gener
wg
associ
appear
anoth
subset
type
cell
could
consequ
bcell
expans
tcelldepend
anca
product
diseas
progress
addit
cell
recent
describ
major
effector
cell
autoimmun
diseas
demonstr
stimul
peripher
blood
mononuclear
cell
posit
patient
wg
autoantigen
result
product
interleukin
il
demonstr
autoimmun
effector
cell
cell
healthi
individu
regulatori
cell
treg
control
activ
immun
effector
cell
increas
evid
balanc
cell
fox
regulatori
cell
disturb
autoimmun
inflammatori
condit
patient
wg
remiss
percentag
fox
treg
shown
increas
cell
function
defici
taken
togeth
vitro
studi
support
pathogen
role
autoimmun
respons
mpo
aav
autoantibodi
could
respons
smallvessel
necrot
vascul
wherea
dysregul
tcell
homoeostasi
may
underli
granulomat
inflamm
evid
pathogen
role
mpoanca
aav
come
anim
model
mpoancaassoci
vascul
xiao
et
al
immun
mice
defici
mpo
mous
mpo
transfer
splenocyt
immun
mice
immunodefici
normal
mice
recipi
mice
develop
pauciimmun
necrot
glomerulonephr
haemorrhag
pulmonari
capillar
similar
clinic
manifest
histopatholog
mpoancaassoci
vascul
addit
transfer
igg
alon
mpoimmun
mice
result
pauciimmun
focal
necrot
glomerulonephr
recipi
demonstr
pathogen
potenti
antimpo
antibodi
addit
studi
show
neutrophil
express
mpo
altern
pathway
complement
besid
antibodi
requir
induc
aav
recipi
mice
defici
factor
b
complement
develop
diseas
also
rat
model
mpoanca
vascul
rat
immun
human
mpo
pathogen
potenti
antimpo
antibodi
demonstr
note
howev
anim
model
wg
gener
seri
earli
observ
suggest
infecti
episod
may
trigger
relaps
aav
studi
upper
airway
involv
wg
show
good
respons
treatment
trimethoprimsulphamethoxazol
longterm
studi
demonstr
chronic
nasal
carriag
staphylococcu
aureu
major
risk
factor
relaps
wg
conjunct
persist
anca
mainten
treatment
trimethoprimsulphamethoxazol
reduc
occurr
relaps
patient
wg
possibl
mechan
wherebi
aureu
could
result
flare
wg
includ
sag
product
bcell
activ
direct
tropism
aureu
endotheli
cell
bind
intern
organ
endotheli
cell
prime
neutrophil
recent
two
studi
shed
new
light
possibl
role
microbi
factor
pathogenesi
aav
first
studi
antibodi
complementari
detect
serum
sampl
patient
vascul
complementari
protein
translat
antisens
dna
strand
encod
complementari
protein
mirror
origin
protein
antibodi
complementari
protein
induc
antiidiotyp
antibodi
react
origin
protein
pendergraft
et
al
immun
mice
complementari
mice
develop
antibodi
complementari
show
homolog
number
microbi
protein
includ
protein
aureu
rais
possibl
infect
aureu
could
lead
antibodi
crossreact
complementari
turn
evok
antibodi
interact
second
studi
describ
antibodi
lysosom
membran
glycoprotein
sensit
specif
marker
pauciimmun
crescent
glomerulonephr
present
neutrophil
endotheli
cell
antibodi
rais
rabbit
abl
activ
neutrophil
induc
apoptosi
human
microvascular
endotheli
cell
importantli
antibodi
induc
pauciimmun
focal
necrot
glomerulonephr
inject
rat
eight
nine
amino
acid
immunodomin
epitop
shown
ident
peptid
fimh
adhes
molecul
fimbria
gram
neg
bacteria
immun
rat
fimh
result
gener
antibodi
crossreact
induc
pauciimmun
glomerulonephr
observ
suggest
infect
gram
neg
bacteria
could
result
loss
toler
could
lead
aav
number
candid
gene
associ
studi
identifi
variant
associ
increas
incid
aav
gene
describ
far
encod
protein
involv
immun
respons
summar
tabl
note
gene
variant
strongli
associ
aav
mhc
gene
also
variant
associ
autoimmun
diseas
includ
rheumatoid
arthriti
type
diabet
system
lupu
erythematosu
sle
suggest
genet
risk
factor
common
autoimmun
diseas
also
appli
aav
differ
variant
within
gene
may
associ
differ
exampl
sle
associ
snp
aav
associ
gwa
aav
current
ongo
may
enlighten
respect
furthermor
ciavatta
et
al
attempt
uncov
potenti
transcript
regulatori
mechan
mpo
disrupt
patient
anca
vascul
examin
mpo
loci
neutrophil
anca
patient
healthi
control
individu
epigenet
modif
associ
gene
silenc
demonstr
level
chromatin
modif
associ
gene
silenc
deplet
mpo
loci
anca
patient
compar
healthi
control
interestingli
patient
control
dna
unmethyl
cpg
island
wherea
healthi
control
dna
methyl
cpg
island
mpo
consist
decreas
level
demethylas
specif
preferenti
express
anca
patient
versu
healthi
control
addit
mechan
recruit
methyltransferas
enhanc
zest
homolog
mpo
loci
shown
mediat
messag
decreas
patient
compar
healthi
control
may
also
epigenet
control
dna
methyl
increas
promot
anca
patient
data
indic
epigenet
modif
associ
gene
silenc
perturb
anca
autoantigenencod
gene
potenti
contribut
inappropri
express
mpo
anca
patient
wg
typic
affect
upper
lower
respiratori
tract
associ
glomerulonephr
although
diseas
affect
organ
system
bodi
clinic
perspect
may
use
think
wg
two
form
predominantli
granulomat
form
mainli
local
diseas
chronic
cours
florid
acut
small
vessel
vasculit
form
character
sever
pulmonari
haemorrhag
andor
rapidli
progress
vascul
sever
vasculit
manifest
two
broad
present
may
coexist
present
sequenti
individu
patient
symptom
sign
upper
respiratori
tract
involv
includ
epistaxi
otalgia
hear
loss
conduct
sensorineur
nasal
septal
involv
cartilagin
collaps
result
characterist
saddl
nose
deform
although
may
present
initi
present
chronic
sinus
may
observ
glottic
subglott
polyp
andor
larg
mediums
airway
stenos
result
granulomat
inflamm
lower
respiratori
tract
manifest
also
includ
granulomat
pulmonari
nodul
without
central
cavit
pulmonari
haemorrhag
rel
asymptomat
result
evanesc
pulmonari
shadow
chest
xray
catastroph
pulmonari
haemorrhag
pulmonari
capillar
associ
respiratori
failur
high
mortal
typic
renal
lesion
focal
segment
necrot
glomerulonephr
pauciimmun
crescent
glomerular
chang
clinic
manifest
includ
hypertens
signific
proteinuria
nephrit
nephrot
syndrom
ultim
protean
clinic
featur
renal
failur
manifest
includ
orbit
involv
granuloma
retin
vascul
peripher
gangren
tissu
loss
vascul
skin
gut
heart
central
nervou
system
andor
peripher
nerv
mononeur
multiplex
salivari
gland
gonad
breast
nonspecif
symptom
malais
fever
weight
loss
growth
failur
arthralgia
arthriti
rel
common
renal
morbid
mortal
major
concern
aav
henc
therapi
aim
preserv
renal
function
recur
theme
treatment
aav
adult
children
treatment
paediatr
aav
broadli
similar
approach
adult
corticosteroid
cyclophosphamid
usual
intraven
dose
per
dose
given
weekli
altern
given
oral
mgkgday
month
plasma
exchang
particularli
pulmonari
capillar
andor
rapidli
progress
glomerulonephr
pulmonaryren
syndrom
routin
employ
induc
remiss
intraven
puls
cyclophosphamid
increasingli
favour
oral
continu
cyclophosphamid
adult
reduc
cumul
dose
less
neutropen
sepsi
thu
increasingli
use
treat
children
aav
well
albeit
without
good
paediatr
evid
follow
lowdos
corticosteroid
azathioprin
mgkgday
maintain
remiss
antiplatelet
dose
aspirin
mgkgday
empir
employ
basi
increas
risk
thrombosi
associ
diseas
process
methotrex
may
role
induct
remiss
patient
limit
wg
less
commonli
use
induct
agent
children
aav
cotrimoxazol
commonli
ad
treatment
wg
particularli
upper
respiratori
tract
involv
serv
prophylaxi
opportunist
infect
possibl
diseasemodifi
agent
recommend
regard
durat
mainten
therapi
base
adult
trial
data
suggest
strongest
predictor
relaps
withdraw
therapi
henc
mainten
therapi
continu
sever
year
gener
therapeut
measur
prophylaxi
osteoporosi
gastrointestin
ulcer
infect
bacteri
protozo
fungal
standard
treatment
aav
use
cyclophosphamid
contribut
morbid
mortal
infect
play
promin
role
diseas
relaps
occur
patient
aav
drug
reduc
withdrawn
newer
immunosuppress
agent
immunomodulatori
strategi
explor
adult
children
treatment
includ
mmf
rituximab
alreadi
report
effect
induc
maintain
remiss
adult
aav
interest
two
recent
random
control
trial
report
efficaci
rituximab
compar
cyclophosphamid
induc
remiss
adult
aav
jone
et
al
report
result
random
trial
rituximab
versu
cyclophosphamid
ancaassoci
renal
vascul
rituxiva
stone
et
al
report
result
rituximab
ancaassoci
vascul
rave
trial
similar
conclus
reach
two
studi
trial
show
rituximab
efficaci
induc
remiss
compar
intraven
cyclophosphamid
rituxiva
trial
oral
cyclophosphamid
rave
trial
howev
number
import
differ
two
trial
rituxiva
trial
patient
randomli
assign
rituximab
group
also
receiv
least
two
dose
intraven
cyclophosphamid
wherea
rave
trial
patient
randomli
assign
rituximab
group
receiv
cyclophosphamid
trial
similar
patient
trial
receiv
intraven
oral
glucocorticoid
therapi
investig
rituxiva
trial
report
sustain
remiss
month
wherea
outcom
data
rave
trial
report
remissioninduct
period
rave
trial
data
confound
use
glucocorticoid
therapi
month
followup
addit
trial
rais
concern
substanti
complic
use
rituximab
immunomodul
agent
ancaassoci
diseas
fewer
advers
event
would
expect
patient
treat
rituximab
compar
cyclophosphamid
unfortun
rave
trial
rate
advers
event
equival
two
studi
group
similarli
rituxiva
studi
patient
rituximab
group
die
patient
control
group
rave
trial
also
show
unexpectedli
elev
number
malign
condit
detect
rel
short
treatment
period
studi
suggest
rituximab
might
consid
option
firstlin
therapi
induct
remiss
ancaassoci
diseas
remain
unclear
whether
rituximab
use
glucocorticoid
alon
combin
intraven
cyclophosphamid
biolog
therapi
also
increasingli
use
treat
children
small
vessel
vascul
includ
aav
anca
neg
vasculitid
agent
use
includ
rituximab
previous
mention
etanercept
infliximab
adalimumab
anakinra
recombin
interleukin
receptor
antagonist
therapi
mainli
reserv
children
fail
standard
treatment
patient
cumul
cyclophosphamid
andor
corticosteroid
toxic
particular
concern
note
european
vascul
studi
group
euva
mycyc
trial
uk
europ
compar
induct
therapi
wg
mpa
use
cyclophosphamid
standard
therapi
versu
mmf
experiment
therapi
first
euva
trial
includ
children
well
adult
activ
recruit
patient
age
year
uk
full
list
past
present
euva
trial
avv
reader
direct
http
wwwvasculitisorg
aav
still
carri
consider
diseaserel
morbid
mortal
particularli
due
progress
renal
failur
aggress
respiratori
involv
therapyrel
complic
sepsi
mortal
paediatr
wg
one
recent
paediatr
seri
period
studi
inclus
largest
paediatr
seri
wg
report
case
chronic
renal
impair
month
follow
despit
therapi
mpa
children
mortal
paediatr
follow
reportedli
less
css
children
recent
seri
quot
relat
mortal
attribut
diseas
rather
therapi
immunopathogenesi
lead
vascular
injuri
pan
probabl
heterogen
base
anim
model
mechan
vascular
inflamm
implic
often
induct
immun
complex
addit
data
support
role
hepat
b
patient
report
higher
frequenc
exposur
parvoviru
cytomegaloviru
pan
patient
compar
control
popul
hiv
also
implic
panlik
ill
addit
report
associ
cancer
haematolog
malign
howev
associ
pan
infect
condit
rare
childhood
streptococc
infect
may
import
trigger
indirect
evid
suggest
bacteri
sag
may
play
role
case
term
pathogenet
mechan
seem
like
immunolog
process
involv
similar
system
vasculitid
includ
immun
complex
complement
possibl
autoantibodi
cell
adhes
molecul
cytokin
growth
factor
chemokin
neutrophil
cell
note
immunohistochem
studi
perform
biopsi
perineur
muscl
vessel
homogen
popul
pan
patient
show
inflammatori
infiltr
consist
mainli
macrophag
lymphocyt
particularli
subset
date
reliabl
anim
model
diseas
panlik
diseas
cynomolgu
macaqu
similar
human
diseas
occur
sporad
snyder
et
al
describ
panlik
ill
aris
spontan
beagl
dog
date
anim
model
provid
insight
pathogenesi
pan
human
furthermor
assum
probabl
genet
predispos
factor
may
make
individu
vulner
develop
pan
also
consid
vasculitid
exampl
link
famili
mediterranean
fever
yalcinkaya
et
al
recent
report
preval
fmf
mutat
children
pan
show
patient
carrier
mefv
mutat
new
eularprintopr
classif
criteria
pan
follow
histopatholog
evid
necrot
vascul
medium
smallsiz
arteri
angiograph
abnorm
aneurysm
stenosi
occlus
mandatori
criterion
plu
one
follow
involv
myalgia
muscl
tender
hypertens
peripher
neuropathi
renal
involv
main
clinic
featur
pan
malais
fever
weight
loss
skin
rash
myalgia
abdomin
pain
arthropathi
addit
featur
includ
ischem
heart
testicular
pain
renal
manifest
haematuria
proteinuria
hypertens
neurolog
featur
focal
defect
haemiplegia
visual
loss
mononeur
multiplex
organ
psychosi
livido
reticulari
also
characterist
featur
occasion
subcutan
nodul
overli
affect
arteri
present
mani
year
treatment
pan
involv
administr
highdos
steroid
addit
cytotox
agent
cyclophosphamid
induc
remiss
empir
aspirin
also
given
antiplatelet
agent
clinician
remiss
achiev
mainten
therapi
daili
altern
day
prednisolon
oral
azathioprin
frequent
util
month
adjunct
plasma
exchang
use
lifethreaten
situat
biolog
agent
infliximab
rituximab
increasingli
use
treatment
cutan
pan
typic
much
less
aggress
agent
commonli
util
includ
lowdos
prednisolon
antiplatelet
agent
colchicin
hydroxychloroquin
azathioprin
howev
case
cutan
pan
may
progress
time
system
form
diseas
therefor
requir
aggress
therapi
ozen
et
al
report
retrospect
seri
childhood
pan
improv
outcom
compar
report
adult
death
patient
endstag
renal
diseas
among
patient
note
howev
seri
patient
classifi
cutan
pan
typic
benign
cours
system
pan
even
though
precis
factor
respons
arteri
damag
ta
unknown
believ
genet
link
immun
respons
unidentifi
antigen
may
incit
autoimmun
damag
cellmedi
humor
pathway
result
diseas
relaps
acut
phase
ta
inflammatori
lesion
origin
vasa
varum
character
perivascular
cuf
mainli
compos
lymphocyt
cytotox
lymphocyt
helper
cell
lumin
stenosi
adventi
small
arteri
due
intim
thicken
rel
common
chronic
stage
ta
intim
fibrosi
often
accompani
wellform
fibrou
atherosclerot
plaqu
calcif
furthermor
autoantibodi
aortic
endotheli
cell
propos
key
factor
pathogenesi
ta
chauhan
et
al
report
patient
ta
show
circul
antiaort
endotheli
cell
antibodi
aaeca
direct
kda
heatshock
protein
hsp
sera
aaecaposit
patient
ta
found
induc
apoptosi
aortic
endotheli
cell
suggest
antibodi
may
role
diseas
pathogenesi
lastli
previou
report
suggest
link
ta
tuberculosi
addit
studi
support
associ
famili
occurr
diseas
extens
report
lead
hypothesi
hereditari
basi
genet
associ
ta
particularli
b
observ
high
estim
multipl
cohort
divers
ethnic
east
asia
south
asia
mexico
addit
hypothesi
made
base
japanes
cohort
even
stronger
associ
identifi
consid
hla
allel
share
motif
glutam
posit
serin
posit
character
b
well
b
data
support
hypothesi
recent
report
use
mexican
cohort
candid
gene
studi
also
report
associ
interleukin
il
gene
polymorph
turkish
cohort
replic
clinic
diagnosi
ta
commonli
challeng
clinician
estim
onethird
children
present
inact
socal
burntout
stage
diseas
clinic
featur
repres
vascular
sequela
rather
activ
vascul
natur
histori
time
onset
symptom
diagnosi
variabl
clinic
spectrum
present
children
ta
differ
adult
howev
hypertens
common
symptom
group
cakar
et
al
recent
report
seri
children
ta
common
complaint
present
headach
abdomin
pain
claudic
extrem
fever
weight
loss
one
child
present
visual
loss
examin
admiss
reveal
hypertens
absent
puls
arteri
bruit
cohort
corticosteroid
still
mainstay
treatment
ta
addit
mtx
azathioprin
mmf
cyclophosphamid
use
children
ozen
et
al
describ
six
children
ta
treatment
steroid
cyclophosphamid
induct
follow
mtx
suggest
effect
safe
childhood
ta
widespread
diseas
antitnf
therapi
may
benefici
surgic
intervent
frequent
requir
allevi
endorgan
ischemia
hypertens
result
vascular
stenos
mortal
rate
children
report
high
outcom
depend
vessel
involv
sever
hypertens
initi
consid
singl
cell
line
vascular
tree
endothelium
recent
emerg
dynam
interfac
respons
environment
stimuli
result
alter
endothelium
gener
repertoir
biolog
respons
play
key
role
control
vascular
homeostasi
haemostasi
inflamm
angiogenesi
consequ
endothelium
display
alter
function
also
lose
integr
endotheli
microparticl
emp
releas
activ
apoptot
endotheli
cell
whole
endotheli
cell
circul
endotheli
cell
cec
detach
injur
vessel
constitut
fundament
featur
injuri
respons
affect
vessel
wall
respons
injuri
regen
mechan
activ
restor
endothelium
integr
past
endotheli
repair
consid
sole
involv
adjac
endotheli
cell
abl
replic
local
replac
lost
cell
sinc
origin
studi
asahara
et
al
becom
obviou
recruit
endotheli
progenitor
cell
epc
repres
addit
mechan
vascular
repair
stem
cell
mobil
bone
marrow
abl
differenti
matur
cell
restor
endotheli
integr
site
vascular
injuri
spectrum
endotheli
respons
consid
dynam
triad
activationinjuryrepair
critic
transform
understand
endotheli
biolog
cec
emp
sensit
biomark
vascular
injuri
monitor
diseas
activ
respons
therapi
children
vascul
addit
preliminari
data
show
alter
endotheli
repair
respons
children
system
vascul
suggest
unfavour
balanc
endotheli
injuri
repair
childhood
vascul
sever
key
aspect
longterm
outcom
vascul
young
remain
ongo
concern
histolog
find
seen
kd
arteri
site
previou
aneurysm
lesion
long
diseas
resolut
appear
indistinguish
atherosclerosi
dhillon
et
al
studi
vascular
respons
reactiv
hyperemia
brachial
arteri
use
highresolut
ultrasound
flowmedi
dilat
endothelialdepend
respons
reduc
kd
patient
compar
control
subject
mani
year
ill
even
patient
without
detect
earli
coronari
arteri
involv
addit
cheung
et
al
studi
cohort
patient
kd
without
coronari
aneurysm
compar
healthi
control
demonstr
reduc
arteri
distens
independ
risk
factor
cardiovascular
morbid
mortal
adult
assess
use
ultrasound
puls
wave
veloc
brachioradi
arteri
segment
carotid
imt
similar
find
also
document
children
pan
thu
longterm
outlook
patient
system
vascul
must
remain
guard
present
time
seri
signific
short
longterm
challeng
loom
field
paediatr
vascul
research
develop
biomark
allow
reliabl
noninvas
monitor
diseas
activ
guid
therapeut
decis
great
clinic
import
furthermor
sever
key
aspect
longterm
cardiovascular
risk
children
system
vascul
describ
emerg
new
therapi
treatment
vascul
children
provid
real
opportun
limit
cyclophosphamid
corticosteroid
exposur
young
includ
mmf
biolog
agent
rituximab
thalidomid
analogu
lenalidomid
amongst
other
none
agent
yet
evid
base
justifi
routin
use
paediatr
vascul
although
mani
increasingli
use
context
individu
case
like
futur
clinic
trial
young
attempt
focu
agent
altern
cyclophosphamid
azathioprin
induct
andor
mainten
remiss
system
vascul
sort
trial
requir
intern
collabor
meaning
patient
number
realiz
remain
import
challeng
vascul
research
children
